| Biomarker ID | 1374 |
| PMID | 24708576 |
| Year | 2014 |
| Biomarker | IGF1 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | NA |
| Odds Ratio/Hazard Ratio/Relative Risk | Univariate: HR: 1.57 (95% CI: 1.02-2.42); Multivariate: 1.67 (95% CI: 1.10-2.52) |
| Effect on Pathways | Pathways include: Skeletal myogenesis control by HDAC and calcium/calmodulin-dependent kinase (CaMK), BAD phosphorylation regulation, Fibroblast growth factor 1, IGF1 signaling pathway, IGF1 receptor signaling through beta-arrestin |
| Experiment | Biochemical Failure Vs No Biochemical Faliure |
| Type of Biomarker | Prognostic |
| Cohort | 160 patients with PCa were selected for the analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | Univariate: p=0.039 Multivariate; p=0.015 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | Time to BF was calculated from date of prostatectomy to the date of known BF, defined as the date of a PSA value ≥0.2 ng/mL (taken at least 6 weeks after surgery) and confirmed by a second PSA value >0.2 ng/mL. Time to BF was censored at the last date of contact for subjects who did not experience BF. |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |